Holen Sie sich die Stockscreener-App
141.20
2.37%
3.27
Handel nachbörslich:
140.36
-0.84
-0.59%
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
Neurocrine’s Next VMAT2 Study Adds Depth To Tardive Dyskinesia Story - Yahoo Finance
The Bull Case For Neurocrine Biosciences (NBIX) Could Change Following Its Next-Gen VMAT2 Phase 2 Trial - Yahoo Finance
Neurocrine’s New Tardive Dyskinesia Trial And What It Means For Valuation - simplywall.st
Exploring Analyst Estimates for Neurocrine (NBIX) Q4 Earnings, Beyond Revenue and EPS - Yahoo Finance Australia
Will Neurocrine Biosciences Inc. stock pay special dividendsJuly 2025 Snapshot & Accurate Buy Signal Notifications - mfd.ru
Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards? - Finviz
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Mediolanum International Funds Ltd Sells 15,811 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NBIX) Projected to Post Earnings on Wednesday - MarketBeat
Trading the Move, Not the Narrative: (NBIX) Edition - Stock Traders Daily
Short Interest in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Declines By 13.9% - MarketBeat
How Investors Are Reacting To Neurocrine Biosciences (NBIX) Launching Phase 2 Trial For Longer-Acting TD Drug - simplywall.st
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring a 31.99% Upside Potential for Investors - DirectorsTalk Interviews
Bank of New York Mellon Corp Has $106.89 Million Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Thrivent Financial for Lutherans Sells 215,514 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Atle Fund Management AB Has $14.41 Million Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NBIX) Valuation Check After New Mid Stage VMAT2 Inhibitor Trial Update - simplywall.st
Y Intercept Hong Kong Ltd Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Inc (NASDAQ:NBIX) Presents a Compelling Mix of Strong Fundamentals and Bullish Technical Setup - Chartmill
AlphaQuest LLC Boosts Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Downgraded to Buy Rating by Wall Street Zen - MarketBeat
Stifel reiterates Buy rating on Neurocrine Bio stock ahead of Q4 results - Investing.com Canada
Summit Global Investments Boosts Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
21,000 Shares in Neurocrine Biosciences, Inc. $NBIX Bought by Hussman Strategic Advisors Inc. - MarketBeat
Does Neurocrine Biosciences (NBIX) Price Weakness Signal A Long Term Opportunity? - simplywall.st
Is Neurocrine Biosciences (NBIX) Offering Value After Recent Share Price Weakness - Yahoo Finance
Assessing Neurocrine Biosciences (NBIX) Valuation After New Phase 2 VMAT2 Tardive Dyskinesia Trial Launch - Yahoo Finance
Higher VMAT2 Target Occupancy Observed in Valbenazine Over Deutetrabenazine Extended-Release Capsules - NeurologyLive
Neurocrine initiates phase 2 study for tardive dyskinesia treatment By Investing.com - Investing.com Nigeria
Neurocrine Biosciences begins Phase II NBI-1065890 trial for TD - Clinical Trials Arena
Neurocrine Biosciences, Inc. (NBIX): Investor Outlook On A 31.63% Potential Upside - DirectorsTalk Interviews
Gainers Report: What is Neurocrine Biosciences Inc.’s TAM (Total Addressable Market)2025 Trading Recap & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Neurocrine Biosciences, Inc. Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia - marketscreener.com
Neurocrine initiates phase 2 study for tardive dyskinesia treatment - Investing.com
Neurocrine Biosciences, Inc. $NBIX Holdings Lifted by Wealth Enhancement Advisory Services LLC - MarketBeat
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia - PR Newswire
New INGREZZA VMAT2 Data vs AUSTEDO XR Might Change The Case For Investing In Neurocrine (NBIX) - simplywall.st
Volume Report: How cyclical is Neurocrine Biosciences Incs revenue stream2025 Volume Leaders & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
(NBIX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Assessing Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Clinical Data And Pipeline Updates - simplywall.st
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $178.00 at UBS Group - MarketBeat
What Analysts Are Saying About Neurocrine Biosciences Stock - Benzinga
UBS Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $178 - 富途牛牛
UBS Adjusts Price Target on Neurocrine Biosciences to $178 From $188, Maintains Buy Rating - marketscreener.com
Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Prime Affordable Growth Stock - Chartmill
Can Neurocrine (NBIX) Keep the Earnings Surprise Streak Alive? - Yahoo Finance
Recap Report: Why is Neurocrine Biosciences Inc stock going up2025 AllTime Highs & Smart Investment Allocation Insights - baoquankhu1.vn
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results - The AI Journal
Neurocrine sets Feb. 11 webcast for Q4 and 2025 year-end financial results - Stock Titan
Aug Analyst Calls: Is Momentus Inc Equity Warrant a momentum stockQuarterly Trade Summary & Expert Curated Trade Setups - baoquankhu1.vn
Rakuten Investment Management Inc. Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) CEO Kyle Gano Sells 36,400 Shares - MarketBeat
Seizert Capital Partners LLC Invests $9.83 Million in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Aug Wrap: What hedge funds are buying Neurocrine Biosciences IncJuly 2025 Intraday Action & Verified Stock Trade Ideas - baoquankhu1.vn
8.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):